ValuEngine Upgrades Midatech Pharma (NASDAQ:MTP) to Buy

ValuEngine upgraded shares of Midatech Pharma (NASDAQ:MTP) from a hold rating to a buy rating in a report issued on Thursday, ValuEngine reports.

Midatech Pharma stock traded down $0.08 during midday trading on Thursday, hitting $1.47. 117,002 shares of the company were exchanged, compared to its average volume of 1,039,966. The stock has a fifty day simple moving average of $1.47. Midatech Pharma has a fifty-two week low of $1.00 and a fifty-two week high of $10.90. The company has a market cap of $4.74 million, a P/E ratio of -3.20 and a beta of 2.75. The company has a current ratio of 2.27, a quick ratio of 2.27 and a debt-to-equity ratio of 0.05.

Midatech Pharma Company Profile

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.

Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.